News

Cytoreduction and JAK Inhibitors Associated With Fewer Thrombotic Events in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis

09/30/2022

Gina Tomaine ;

Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.

Both conventional cytoreduction...

09/30/2022

Oncology

News

FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

08/31/2022

Allison Casey ;

On August 26, 2022, the FDA approved pemigatinib for adult patients with relapsed or refractory myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement.

On August 26, 2022, the FDA...

08/31/2022

Oncology

News

Momelotinib Associated With Positive Survival Outcomes in Patients With Myelofibrosis: SIMPLIFY Trials

08/04/2022

Gina Tomaine ;

In the phase 3 SIMPLIFY trials, momelotinib demonstrated excellent OS and leukemia-free survival in patients with myelofibrosis, as well as activity against anemia, symptoms, and splenomegaly.

In the phase 3 SIMPLIFY trials,...

08/04/2022

Oncology

Conference Coverage

Momelotinib vs Danazol for Patients With Myelofibrosis: Findings From the MOMENTUM Trial

06/06/2022

Amber Denham ;

Findings from the phase 3 MOMENTUM trial demonstrate the superior efficacy of momelotinib vs danazol for symptomatic and anemic patients with myelofibrosis previously treated with a JAK inhibitor.

Findings from the phase 3...

06/06/2022

Oncology

News

Symptom Burden and Quality of Life With Cytoreductive Therapy in Essential Thrombocythemia and Polycythemia Vera

03/30/2022

John Otrompke , BA, JD;

Findings from an analysis of the MPN-RC 111 trial help inform decisions regarding cytoreductive treatment timing and goals for patients with essential thrombocythemia and polycythemia vera.

Findings from an analysis of the...

03/30/2022

Oncology

News

Imetelstat Associated With High OS in Patients With R/R MF

03/21/2022

John Otrompke , BA, JD;

Imetelstat was found to be associated with a significantly lower risk of death compared with “best available therapy” in patients with intermediate-to-high risk MF who had previously been treated with JAK inhibitors.

Imetelstat was found to be...

03/21/2022

Oncology

News

Researchers Further Characterize MPN First Identified in 1991, Offer Genetic Clues

03/08/2022

Researchers have identified 15 patients with a distinct MPN, which they propose naming “clonal megakaryocyte dysplasia.” This new disorder, according to the researchers, is distinct from pre-PMF.

Researchers have identified 15...

03/08/2022

Oncology

News

Antiplatelet, Anticoagulation Therapies Significantly Increase Bleeding Risk for MPNs

02/01/2022

A retrospective study found antiplatelet and anticoagulation therapies significantly increase the risk of bleeding in patients with MPNs without affecting mortality.

A retrospective study found...

02/01/2022

Oncology

News

Sotatercept is Safe, Effective for MPN-Associated MF Anemia

01/20/2022

Treatment with sotatercept was found to be safe and effective for anemic patients with MPN-associated MF, according to phase 2 data presented at the 2021 ASH Annual Meeting.

Treatment with sotatercept was...

01/20/2022

Oncology

News

Pulmonary Hypertension Suggest Worse Patient Outcomes in MPNs, CV Diseases

11/09/2021

Novel data presented at the 2021 ASH Annual Meeting investigated associations between MPNs and cardiovascular diseases. Further, pulmonary hypertension suggest worse patient outcomes with further investigation needed.

Novel data presented at the 2021...

11/09/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology